Tempus AI (TEM.US) Price Target 2026/2027: 35% Upside – Rating and Stock Analysis

46,47
-0,49%
Price history for Tempus AI (TEM.US) – stock price at 46.47 $, August 2026
Tempus AI stock price – price development 2026. Updated Aug 6, 2026.
Share this analysis:

Tempus AI Price Target 2026: Analysts See 35% Upside

The average price target for Tempus AI is $62.79. This price target represents the analysts' view of the stock price over the next 12 months. The stock may be undervalued, because the price target is higher than the current price. The stock is 35,12% below the target, which can point to potential returns within the next 12 months if the analysts' view proves right. Also consider the stock's valuation ratios such as P/E, P/S and P/B, plus the technical analysis further down the page, for the full picture.

Is Tempus AI overvalued or undervalued?

Tempus AI is currently undervalued with a gap of 35.1% relative to the price target.


The current price is $46.47, which places Tempus AI in the undervalued category. The stock is considered undervalued when the price is below $56.51, and overvalued when the price exceeds $69.07.


The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For Tempus AI, the fair value range lies between $56.51 and $69.07.


See the full price target analysis for Tempus AI →

Analyst Ratings for Tempus AI stock in 2026: Buy

12 analysts cover Tempus AI. Analysts are mostly neutral — 50% recommend Hold. The average price target is $62.79, which gives an upside of 35.1% from the current price.

Consensus: Buy (3.83/5)
Strong Buy
4 (33.3%)
Buy
2 (16.7%)
Hold
6 (50%)
Strong Sell Sell Hold Buy Strong Buy
3.83 out of 5 based on 12 analysts

About Tempus AI – Health Information Services

Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a collaboration with united therapeutics to study use of AI to detect patients at risk for pulmonary hypertension. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois. Read more about the company

Key Figures for Tempus AI

$ 8,5B Market cap
$ 1,4B Revenue
Health Information Services Industry
- P/E
5.93 P/S
17.79 P/B
USA Listed on exchange
tempus.com Website
Sundhed Sector

What kind of stock is Tempus AI?

Speculative stock

Tempus AI is classified as a speculative stock.

Score Overview for Tempus AI

💰 Value Score 10/100 (Very Low)
⭐ Quality Score 15/100 (Very Low)
🚀 Momentum Score 12/100 (Very Low)
📊 Total Score 12/100

⚠️ 6 red flags identified 4 critical

Our analysis has identified 6 potential risk factors in Tempus AI that investors should be aware of.

🚨 High debt: The debt-to-equity ratio is 1,544% – the company carries considerably more debt than equity, which raises the financial risk.
⚠️ Weak financial health: The Piotroski score is only 3/9 – the company shows signs of weakened profitability, liquidity or capital structure.
🚨 Weak balance sheet (elevated risk): Altman Z2 is -1.29 – the balance sheet is measurably weaker than average. This is a risk signal based on the numbers, not a bankruptcy prediction.
⚠️ Negative profit margin: The profit margin is -17.8% – the company is losing money on its operations.
🚨 Negative return on equity: ROE is -67.4% – the company is generating a negative return for shareholders.
🚨 High short interest: 30.5% of the shares are sold short – many professional investors are betting on price declines.

📈 Valuation

The P/S ratio is 5.9 (high — the market pays a premium for the revenue). The P/B ratio is 17.8.

🏦 Financial Health

The Piotroski score is 3 out of 9 — weak financial health, be careful. Altman Z2 is -1.29 (weak balance sheet — elevated risk). The debt-to-equity ratio (D/E) is 1,543.8% — high debt, which raises the risk.

🚀 Momentum & Short Interest

Short interest is 30.45% — very high, the market is skeptical.

Insider Trading in Tempus AI 2026: The Signal Is negative

In 2026, insiders at Tempus AI have made 20 transactions, all of which were sales. On a net basis, insiders took 69,164,425 $ out of the stock. Active insiders include Eric P Lefkofsky, Andrew Polovin, Ryan M Bartolucci and others.

Short-Term Signal (3 months): No activity

There has been no insider trading in the last 3 months.

Long-Term Signal (all transactions): Negative

Insiders have exclusively sold shares in the recent period. This can suggest management sees limited opportunity.

Across the last 20 transactions: 0 purchases and 20 sales. A net 69,164,425 $ out of the stock.

Latest sale: Eric P Lefkofsky sold 166,250 shares at 46 $ each on 2026-03-26.

Who is selling: Eric P Lefkofsky, Andrew Polovin, Ryan M Bartolucci, Ryan Fukushima, James William Rogers and others.

Latest Insider Trades in Tempus AI (2026)

The table shows the last 20 reported insider transactions in Tempus AI. Green rows are purchases, red rows are sales. The data is based on official filings.

Transaction date Name Type Number of shares Price per share ($) Total amount ($)
2026-03-26 Eric P Lefkofsky Sell 166,250 46 7,710,675
2026-02-20 Andrew Polovin Sell 10,949 60 660,334
2026-02-19 Ryan M Bartolucci Sell 2,902 59 171,363
2026-02-19 Ryan Fukushima Sell 9,592 59 566,408
2026-02-19 James William Rogers Sell 10,084 59 595,460
2026-02-19 Erik Phelps Sell 9,464 59 562,446
2026-02-19 Eric P Lefkofsky Sell 166,250 59 9,787,138
2026-02-19 Andrew Polovin Sell 8,143 59 480,844
2026-02-02 David R Epstein Sell 370 59 21,982
2026-01-28 Eric P Lefkofsky Sell 166,250 66 10,899,350

Who is buying and selling Tempus AI shares in 2026?

The following insiders have sold shares: Eric P Lefkofsky, Andrew Polovin, Ryan M Bartolucci, Ryan Fukushima, James William Rogers and others. In total, 69,164,425 $ was sold across 20 transactions. Insider trades are legal transactions in which executives and board members buy or sell shares of their own company. These transactions are reported to the SEC and are publicly available.

Tempus AI Short Selling 2026: 30.5% Sold Short

Extremely shorted: 30.5% of the free float
Short % of free float
30.5%
Assessment
Extremely shorted
Short squeeze risk
Very High
Data source
SEC
Updated daily
The stock has an extremely high share of short selling. More than 20% of the freely traded shares are sold short, which is unusual and can point to great skepticism among institutional investors. The risk of a short squeeze on positive news is considerable.

What does this mean for you as an investor?
A short interest of 30.5% means that 30.5% of the freely traded shares in Tempus AI have been borrowed and sold by investors betting on falling prices. On positive surprises (e.g. a strong earnings report), short sellers can be forced to buy back shares quickly to close their positions, which can cause a short squeeze with sharp price gains in a short time.

Data is updated daily based on official filings with the SEC.
Short Interest Scale
0% 2% 5% 10% 20%+
Low Moderate High Very High Extreme
30.5%

When Does Tempus AI Report Earnings?

The next earnings date for Tempus AI is not yet available. Check the company's investor calendar for more information.



Technical Analysis of Tempus AI 2026 – Signal: Strong Sell

Overall Technical Signal: Strong Sell

Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated August 6, 2026.

Technical analysis of Tempus AI (TEM.US) – RSI 45, MACD negative (bearish), daily candlestick chart August 2026
Tempus AI technical analysis – candlestick chart with RSI and MACD. Updated Aug 6, 2026.

Trend Analysis of Tempus AI, Inc. Class A Common Stock

Tempus AI, Inc. Class A Common Stock is in a short-term downtrend. The price of $46.70 is 5.3% below the 20-day average ($49.30). Medium term, the picture is negative: the price is 8.5% below the 50-day average ($51.05). Long term, the stock is 20.5% below the 200-day average ($58.73), which signals a long-term downtrend.

Death Cross: The 50-day average (51.05) is below the 200-day average (58.73), which is a classic bearish signal for Tempus AI, Inc. Class A Common Stock.

Is Tempus AI, Inc. Class A Common Stock overbought or oversold?

Tempus AI, Inc. Class A Common Stock has an RSI of 44.9. The stock sits in the lower part of the neutral zone, which points to weak momentum without being oversold. In the current downtrend, be careful about reading this as a buying opportunity.

MACD Analysis for Tempus AI, Inc. Class A Common Stock

Daily MACD: MACD is negative (-2.322), which means the short-term trend is bearish (the 12-day EMA is below the 26-day EMA). MACD is below the signal line (-2.187) by 0.135, which confirms growing negative momentum in the downtrend.

Weekly MACD: MACD5 is negative (-2.922), which indicates a broader bearish long-term trend. MACD5 is above the signal line (-3.184) by 0.262, which suggests the negative long-term momentum is fading – a bigger trend reversal could be ahead.

Overall MACD assessment: Both the daily and weekly trend are bearish (MACD negative). However, momentum shows signs of improving on a weekly basis – a potential trend reversal could be ahead, but it is not confirmed yet.

Risk Profile for Tempus AI, Inc. Class A Common Stock

Tempus AI, Inc. Class A Common Stock has an annual standard deviation of 66.2%, which classifies the stock as high risk. Sizeable price swings are normal, and the stock requires a higher risk tolerance.

Overall Technical Conclusion for Tempus AI, Inc. Class A Common Stock

Trend: Negative. The price trades below SMA50 and SMA200.

MACD trend (zero line): Daily bearish (-2.322). Weekly bearish (-2.922).

MACD momentum (signal): Daily falling. Weekly rising.

RSI: 44.9 – neutral.

Technical signal: Strong Sell

The price is in a downtrend (below SMA50/SMA200) and MACD is negative on both a daily and weekly basis. Avoid buying and consider closing existing positions.

Frequently Asked Questions About Tempus AI stock in 2026

Should you buy Tempus AI stock now?
No, the technical signal for Tempus AI is currently SELL. Tempus AI trades at $46.47 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -2.322 with falling momentum (signal: -2.187); RSI is at 44.9 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $62.79 points to 35.1% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Tempus AI stock?
The average analyst price target for Tempus AI is $62.79. The current price is $46.47, which gives an upside of 35.1%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $56.51 and $69.07.
Is Tempus AI a dividend stock?
No, Tempus AI does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Tempus AI stock?
Tempus AI is rated as a stock with high risk. the annual standard deviation is 66.2%, which classifies the stock as high risk.
Is Tempus AI overvalued?
No, Tempus AI is considered undervalued based on the analyst price target (35.1% upside). Tempus AI has the following valuation ratios: a P/S ratio of 5.9, a P/B ratio of 17.8. The analyst price target suggests that the stock is undervalued by 35.1%.
Is Tempus AI overbought?
No, Tempus AI is not overbought. RSI is at 44.9 (neutral zone). The technical indicators show: RSI is at 44.9 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 5.7% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Tempus AI earnings report?
The date of the next earnings report for Tempus AI has not been published yet. Check the company's investor calendar for updates.
Is Tempus AI shorted?
Yes, Tempus AI is shorted with 30.5% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. Data is updated daily based on official filings with the SEC.
Are insiders buying Tempus AI stock?
No, insiders are not buying Tempus AI shares – they are net sellers. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 69,164,425 $ sold. Active sellers include Eric P Lefkofsky, Andrew Polovin, Ryan M Bartolucci and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Tempus AI a good stock?
Based on our total score, Tempus AI is rated as a disastrous stock with a total score of 12 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 10/100, Quality: 15/100, Momentum: 12/100. In addition: analysts see 35.1% upside to the price target; technical signal: Strong Sell. Whether Tempus AI is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Tempus AI stock?
The outlook for Tempus AI based on current data: the average analyst price target is $62.79 (+35.1%); the stock is in a downtrend (below SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Tempus AI stock falling?
Tempus AI is falling right now. The technical indicators show: the price is 5.7% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 30.5% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Tempus AI go?
The average analyst price target for Tempus AI is $62.79, which corresponds to a potential gain of 35.1% from the current price of $46.47. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Tempus AI fall?
We lack enough history to give a specific floor for Tempus AI. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Tempus AI do?
Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical com... The company belongs to the Sundhed sector, more specifically the Health Information Services industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Tempus AI as an investment.
Did Tempus AI raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Tempus AI. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Tempus AI making money or losing money?
No, Tempus AI is currently not making money — the company is losing money with a negative profit margin of -17.8%, a noticeable loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Tempus AI go bankrupt?
The bankruptcy risk of Tempus AI is rated as elevated. Altman Z2 (a model for assessing financial distress) is -1.29 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 3 — which is weak. Debt relative to equity is 1,544% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Tempus AI have a lot of debt?
Yes, Tempus AI has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 1,544%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.